BLOOMLIFE

Bloomlife is a maternal health technology company that sells a connected care platform for monitoring high-risk pregnancies outside the clinic. Its Bloomlife Connects program combines cellular-enabled, FDA-cleared blood pressure and blood glucose remote patient monitoring (RPM) devices, support for continuous glucose monitors and finger-stick testing, patch-based fetal monitoring, and digital health screening using standardized instruments such as PHQ-9 and EPDS alongside customizable assessments for symptoms, social determinants of health and mental health risk. The platform is designed to replace paper logs, manual data entry and some in-clinic appointments with automated data capture that flows natively into the practice's EMR.

For clinicians, the product offers customizable clinical escalation protocols and smart notifications so teams can triage patients across a high-risk population, plus configurable rules governing where monitoring data goes, who reviews it and at what interval. The company emphasizes workflow integration, tailored staff training, ongoing optimization and enterprise-grade cybersecurity. Its fetal monitoring product is presented as a patch-based home solution intended to allow non-stress tests to be performed outside the exam room; it is FDA 510(k)-cleared (#K222327) for maternal and fetal heart rate, with uterine activity and the full NST indication still pending clearance and the device labeled investigational for those uses.

Earlier consumer-facing work included a wearable for tracking contractions in pregnancy, which was shown at CES 2017 as a TechCrunch Hardware Battlefield finalist.

Founding story

Bloomlife was founded in 2014; TechCrunch lists Eric Dy as founder.

Business model

Bloomlife sells its RPM program to healthcare providers and organizations. Providers can bill for the monitoring using existing CPT codes, with reimbursement from Medicaid and commercial payers; the company positions the program as requiring no financial commitment from the practice and as a route to new billable services and increased practice capacity.

Revenue is tied to provider adoption of a reimbursed remote patient monitoring program; Bloomlife states it is in network with 19 insurance companies and Medicaid, connects with patients' insurance to limit out-of-pocket costs, and its devices/services are FSA/HSA eligible.

Traction

Reported metrics include an NPS of 75, in-network status with 19 insurance companies plus Medicaid, and internal outcome claims of a 260% improvement in adherence to home blood pressure screening versus standard of care and a 30% reduction in poorly controlled blood pressure at clinical check-ups among Bloomlife Connects patients. A TechCrunch profile listed $29M raised as of January 2025.

Latest developments

In September 2024 the company announced a $12.2 million Series A led by Kapor Capital and Noshaq with participation from RH Capital, 15th Rock Ventures, The Grove Foundation, Stardust Equity and Lean Square, intended to fund product development and expansion of its remote care suite. Its current commercial focus is the Bloomlife Connects program covering blood pressure and glucose RPM, health screening and fetal monitoring.